위장관암 환자의 옥살리플라틴 항암화학요법으로 인한 말초신경병증, 증상경험, 디스트레스와 삶의 질
Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: This study was conducted to identify the level of oxaliplatin-induced peripheral neuropathy (OIPN), symptoms, distress, and quality of life (QoL) in gastrointestinal (GI) cancer patients and to identify the factors influencing QoL. Methods: A total of 123 patients were recruited for this cross-sectional study. Surveys used were the Therapy-Induced Neuropathy Assessment Scale (TNAS) for OIPN, the MD Anderson Symptom Inventory (MDASI-GI) for general symptoms associated with gastrointestinal cancer and its treatment, a distress thermometer, and the Euro Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D) for QoL. Results: The patients were classified into three groups based on their treatment completion time (current, completed less than one year ago, completed more than one year ago). The scores of MDASI-GI and distress were significantly lower in patients who had completed chemotherapy compared to those who were undergoing treatment (p=.04 and .02 respectively). However, TNAS score was significantly higher in patients who completed chemotherapy less than one year ago than the other two groups (p=.001). In multivariate regression models, the OIPN and distress or general symptoms were identified as factors associated with QoL. Conclusion: In this study, we identified the symptoms that are factors related to the QoL in patients with GI cancer. In particular, the symptoms of OIPN are reported at significantly increased levels for patients who have finished chemotherapy less than one year ago, so efforts to prevent and manage the symptoms of OIPN are needed in this timeframe. To improve QoL of patients with GI cancer, continuous attention and care are required not only during the treatment of cancer but also after the completion of treatment.
Abstract
Purpose: This study was conducted to identify the level of oxaliplatin-induced peripheral neuropathy (OIPN), symptoms, distress, and quality of life (QoL) in gastrointestinal (GI) cancer patients and to identify the factors influencing QoL. Methods: A total of 123 patients were recruited for this cross-sectional study. Surveys used were the Therapy-Induced Neuropathy Assessment Scale (TNAS) for OIPN, the MD Anderson Symptom Inventory (MDASI-GI) for general symptoms associated with gastrointestinal cancer and its treatment, a distress thermometer, and the Euro Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D) for QoL. Results: The patients were classified into three groups based on their treatment completion time (current, completed less than one year ago, completed more than one year ago). The scores of MDASI-GI and distress were significantly lower in patients who had completed chemotherapy compared to those who were undergoing treatment (p=.04 and .02 respectively). However, TNAS score was significantly higher in patients who completed chemotherapy less than one year ago than the other two groups (p=.001). In multivariate regression models, the OIPN and distress or general symptoms were identified as factors associated with QoL. Conclusion: In this study, we identified the symptoms that are factors related to the QoL in patients with GI cancer. In particular, the symptoms of OIPN are reported at significantly increased levels for patients who have finished chemotherapy less than one year ago, so efforts to prevent and manage the symptoms of OIPN are needed in this timeframe. To improve QoL of patients with GI cancer, continuous attention and care are required not only during the treatment of cancer but also after the completion of treatment.
참고문헌 (28)
- "Cancer facts and figures"[URL]
- Mols F, "Chemotherapyinduced peripheral neuropathy and its association with quality of life: a systematic review", Support Care Cancer, 22, pp.2261~2269 (2014)
- Esther Kim JE, "A review of the prevalence and impact of multiple symptoms in oncology patients", J Pain Symptom Manage, 37, pp.715~736 (2009)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Sereno M, "Oxaliplatin induced-neuropathy in digestive tumors", Crit Rev Oncol Hematol, 89, pp.166~178 (2014)
- Bennett BK, "Impact of oxaliplatin-induced neuropathy: a patient perspective", Support Care Cancer, 20, pp.2959~2967 (2012)
- André T, "Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial", J Clin Oncol, 27, pp.3109~3116 (2009)
- Kolb NA, "The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling", JAMA Neurol, 73, pp.860~866 (2016)
- Tofthagen C, "Oxaliplatininduced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors", Support Care Cancer, 21, pp.3307~3313 (2013)
- 오복자, "대장암 ․ 위암 환자의 항암화학요법 시기에 따른 암 증상, 우울 및 삶의 질의 변화: 전향적 종단 연구", 성인간호학회지, 29(3), pp.313~322 (2017), 한국성인간호학회[DOI]
- "NCCN guidelines for distress management, version 2" (2018)[URL]
- 권은진, "한국 유방암 생존자들의 디스트레스와 삶의 질", Asian Oncology Nursing, 12(4), pp.289~296 (2012), 대한종양간호학회[DOI]
- 김경연, "암 환자의 말초신경병증 관련 일상활동장애와 삶의 질: 심리적 디스트레스의 매개효과", Journal of Korean Academy of Nursing, 45(5), pp.661~670 (2015), 한국간호과학회
- 백영애, "항암화학요법을 받고 있는 한국 대장암 환자의 삶의 질 영향 요인", Journal of Korean Academy of Nursing, 45(4), pp.604~612 (2015), 한국간호과학회
- 양영희, "수술후 화학요법받는 위암환자의 부작용 증상, 피로 및 삶의 질과의 관계", 성인간호학회지, 14(2), pp.204~211 (2002), 한국성인간호학회
- Padman S, "Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--crosssectional cohort study of patients with colorectal cancer surviving at least 2 years", Support Care Cancer, 23, pp.861~869 (2015)
- Lee JY, "Assessment and comparison of utility for heart failure using VAS (visual analogue scale), TTO (time trade-off), and EQ-5D (Euro-Qol-5 dimensions)", pp.2016
- Kim TH, "Validity and reliability evaluation for EQ-5D in the general population of south Korea", pp.2012
- Mendoza TR, "Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the treatment-induced neuropathy assessment scale", J Pain, 16, pp.1032~1043 (2015)
- Wang XS, "Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer(the MDASI-GI)", Cancer, 116, pp.2053~2063 (2010)
- Donovan KA, "Validation of the distress thermometer worldwide: state of the science", Psychooncology, 23, pp.241~250 (2014)
- 김수현, "A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy", Journal of Clinical Neurology, 14(1), pp.81~89 (2018), 대한신경과학회[DOI]
- Ezendam NP, "Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry", Gynecol Oncol, 135, pp.510~517 (2014)
- Bao T, "Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk", Breast Cancer Res Treat, 159, pp.327~333 (2016)
- Curt GA, "Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition", Oncologist, 5, pp.353~360 (2000)
- Kroenke K, "Somatic symptoms in cancer patients trajectory over 12 months and impact on functional status and disability", Support Care Cancer, 21, pp.765~773 (2013)
- 김윤선, "노인 위암 환자의 디스트레스와 삶의 질: 사회적 지지의 매개 효과", 성인간호학회지, 29(5), pp.536~546 (2017), 한국성인간호학회[DOI]
- 김종규, "EQ-5D Index 이용 성인 암 환자의 인구사회학적 특성별 건강관련 삶의 질 측정 -국민건강영양조사를 중심으로-", 디지털융복합연구, 11(8), pp.281~291 (2013), 한국디지털정책학회